



## Clinically Important Pathogens, Antimicrobial Resistance in ESKAPE Group of Bacteria

Guest Editors:

**Prof. Dr. Pavel Bostik**

Faculty of Medicine and Faculty Hospital, Charles University, Hradec Kralove, Czech Republic

**Prof. Dr. Milan Kolar**

Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University, Olomouc, Czech Republic

Deadline for manuscript submissions:

**closed (31 May 2023)**

### Message from the Guest Editors

Clinical medicine today can be characterized by an exponential increase in knowledge in all its disciplines, which brings significant improvements in both the diagnostic and therapeutic fields. However, it is necessary to point out one area which, despite the achieved successes, still represents a serious therapeutic problem. This area includes bacterial infections, the importance of which has been steadily increasing in recent years. The main reasons for this rise can be defined by the following points:

- Bacterial infections are often becoming endogenous, i.e., the etiologic agent comes from the human microflora;
- Infections by atypical or previously rarely detected microorganisms are on the rise;
- Resistance of bacteria to antibacterial drugs (AMR) and the associated risk of antibiotic treatment failure are increasing;
- The number of immunocompromised patients is increasing;
- Invasive diagnostic and treatment procedures affecting the human microbiome are increasingly used.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Nicholas Dixon

School of Chemistry and  
Molecular Bioscience, University  
of Wollongong, Wollongong, NSW  
2522, Australia

## Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

## Contact Us

---

*Antibiotics* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/antibiotics  
antibiotics@mdpi.com  
X@antibioticsmdpi